The biotech financing environment appears poised to remain a top concern for young start-up companies, which are having to make difficult decisions about capital allocation. The number of biotechs that are down to one or two years of cash is eye-catching, according to a new report from the consulting firm EY covering the state of the biotech industry.
Key Takeaways
- More than half of emerging biotechs do not have enough cash to sustain operations for two years.
- M&A could return investors to biotech and big pharma has unprecedented firepower for deals.
- Yet, FTC’s recent scrutiny has created uncertainty that could defer deals
EY’s Beyond Borders report was released on 6 June, coinciding with the BIO International Convention in Boston on 5-8 June, spotlighting what the firm called
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
